Merck & Co., Inc. Stock Euronext Paris
Equities
MRK
US58933Y1055
Pharmaceuticals
Sales 2024 * | 64.18B 59.92B | Sales 2025 * | 68.68B 64.13B | Capitalization | 329B 307B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 18.21B | Net income 2025 * | 22.25B 20.77B | EV / Sales 2024 * | 5.41 x |
Net Debt 2024 * | 18.6B 17.37B | Net Debt 2025 * | 7.28B 6.8B | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.5
x | Employees | 71,000 |
Yield 2024 * |
2.38% | Yield 2025 * |
2.52% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
1st Jan change | Capi. | |
---|---|---|
+55.32% | 819B | |
-6.75% | 351B | |
+10.68% | 298B | |
+16.57% | 242B | |
+2.04% | 225B | |
+13.31% | 217B | |
+8.48% | 168B | |
-2.81% | 158B | |
+0.20% | 120B |